REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug cocktail shows promise for tough blood cancers, but study halted early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control TerminatedThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo tried for tough blood cancers
Disease control TerminatedThis early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Promising combo for tough blood cancer hits snag, study stopped early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising combo for tough leukemia hits roadblock: trial stopped early
Disease control TerminatedThis early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC